Development of Drugs to Treat NAFLD/NASH using Quantitative Systems Pharmacology Modeling

Authors: Yang K
Conference: AAPS
Keywords: drug development, lipotoxicity, Non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), QSP (quantitative systems pharmacology) modeling software
Software: NAFLDsym®
Division: Quantitative Systems Pharmacology (QSP)

Session Description and Objectives

Description

  • This session will provide scientific background and overview of the application of quantitative systems pharmacology (QSP) modeling in drug development to treat NALFD/NASH
  • A case study will be presented where NAFLDsym , a QSP modeling platform, was employed to support clinical development of an acetyl CoA carboxylase inhibitor ( ACCi ) to treat NAFLD/NASH

Objectives

  • To explore components and scientific backgrounds of quantitative systems pharmacology (QSP) modeling of NAFLD/NASH
  • To understand the mechanistic representation of pathophysiology of NAFLD/NASH within NAFLDsym
  • To understand how QSP modeling was employed to support clinical development of an ACCi to treat NAFLD/NASH

By Kyunghee Yang

2019 AAPS Annual Meeting PharmSci 360, November 3-6, 2019, San Antonio, Texas